Suzhou Fujilai Pharmaceutical

Suzhou Fujilai Pharmaceutical is a leading Chinese pharmaceutical company specializing in the research, development, and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. The company is recognized as one of the world's largest producers of lipoic acid series products, which are utilized globally for treating diabetic neuropathy and as high-end nutritional supplements. Beyond its flagship lipoic acid portfolio, Fujilai produces a range of other APIs including phosphatidylcholine and various amino acid derivatives. The company provides comprehensive CDMO services, leveraging its GMP-compliant facilities to support global pharmaceutical clients. Headquartered in Changshu, Suzhou, the company is publicly traded on the Shenzhen Stock Exchange.